Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by DUNBAR, P. R.
Right arrow Articles by NEALE, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DUNBAR, P. R.
Right arrow Articles by NEALE, T. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

other

IMMUNOASSAY OF PLATELET-DERIVED GROWTH FACTOR IN THE PLASMA OF PATIENTS WITh SCLERODERMA

P. R. DUNBAR, A. HARRISON, M. M. CORKILL and T. J. NEALE

Department of Medicine Wellington School of Medicine, University of Otago P. O. Box 7343, Wellington South, New Zealand

It has been postulated that platelet—derived growth factor (PDGF) is responsible for the abnormal fibroblast proliferation observed in scleroderma. In one previous study, plasma samples from patients with scleroderma caused increased mitogenesis in cultured fibroblasts, suggesting that the pathogenesis of scleroderma is related to increased plasma PDGF concen trations. To test this hypothesis, we used a sensitive, monoclonal antibody—based ELISA to measure PDGF in the plasma of 12 scleroderma patients. A rigorous sampling protocol prevented false elevations in plasma PDGF levels from ex vivo platelet degranulation: ß-thromboglobulin concentrations were measured in each plasma sample to monitor platelet lysis. Plasma PDGF concentrations in the scleroderma patients were not statistically different from those observed in age- and sex—matched normal controls, and patients with RA. While it is possible that changes in PDGF activity at a local level alter fibroblast function, we cannot conclude that elevated plasma concentrations of PDGF play a role in the pathogenesis of scleroderma.

KEY WORDS: Scleroderma, Systemic sclerosis, Rheumatoid arthritis, Platelet-derived growth factor, ß-Thromboglobulin, Enzyme-linked immunoassay, monoclonal antibody


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
E Balada, C P Simeon-Aznar, J Ordi-Ros, M Rosa-Leyva, A Selva-O'Callaghan, J Pardos-Gea, V Fonollosa-Pla, and M Vilardell-Tarres
Anti-PDGFR-{alpha} antibodies measured by non-bioactivity assays are not specific for systemic sclerosis
Ann Rheum Dis, July 1, 2008; 67(7): 1027 - 1029.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.